Predictive Factors for Local Recurrence in Breast Cancer

Clarke, 2005, Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials, Lancet, 366, 2087, 10.1016/S0140-6736(05)67887-7 Bartelink, 2007, Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-Year results of the randomized boost versus no boost EORTC 22881-10882 trial, J Clin Oncol, 25, 3259, 10.1200/JCO.2007.11.4991 van de Vijver, 2002, A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med, 347, 1999, 10.1056/NEJMoa021967 Paik, 2004, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, 351, 2817, 10.1056/NEJMoa041588 Wang, 2005, Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer, Lancet, 365, 671, 10.1016/S0140-6736(05)70933-8 Liu, 2007, The prognostic role of a gene signature from tumorigenic breast-cancer cells, N Engl J Med, 356, 217, 10.1056/NEJMoa063994 van 't Veer, 2002, Gene expression profiling predicts clinical outcome of breast cancer, Nature, 415, 530, 10.1038/415530a Buyse, 2006, Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer, J Natl Cancer Inst, 98, 1183, 10.1093/jnci/djj329 Mook, 2009, The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study, Breast Cancer Res Treat, 116, 295, 10.1007/s10549-008-0130-2 Mook, 2007, Individualization of therapy using Mammaprint: From development to the MINDACT trial, Cancer Genomics Proteomics, 4, 147 Zujewski, 2008, Trial assessing individualized options for treatment for breast cancer: The TAILORx trial, Future Oncol, 4, 603, 10.2217/14796694.4.5.603 Kreike, 2009, Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients, Clin Cancer Res, 15, 4181, 10.1158/1078-0432.CCR-08-2644 Nuyten, 2006, Predicting a local recurrence after breast-conserving therapy by gene expression profiling, Breast Cancer Res, 8, R62, 10.1186/bcr1614 Mamounas, 2010, Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20, J Clin Oncol, 28, 1677, 10.1200/JCO.2009.23.7610 Fourquet, 1989, Prognostic factors of breast recurrence in the conservative management of early breast cancer: A 25-year follow-up, Int J Radiat Oncol Biol Phys, 17, 719, 10.1016/0360-3016(89)90057-6 Veronesi, 1995, Local recurrences and distant metastases after conservative breast cancer treatments: Partly independent events, J Natl Cancer Inst, 87, 19, 10.1093/jnci/87.1.19 Elkhuizen, 1998, Local recurrence after breast-conserving therapy for invasive breast cancer: High incidence in young patients and association with poor survival, Int J Radiat Oncol Biol Phys, 40, 859, 10.1016/S0360-3016(97)00917-6 Fowble, 1994, The influence of young age on outcome in early stage breast cancer, Int J Radiat Oncol Biol Phys, 30, 23, 10.1016/0360-3016(94)90515-0 Borger, 1994, Risk factors in breast-conservation therapy, J Clin Oncol, 12, 653, 10.1200/JCO.1994.12.4.653 Schnitt, 1994, The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy, Cancer, 74, 1746, 10.1002/1097-0142(19940915)74:6<1746::AID-CNCR2820740617>3.0.CO;2-Y Park, 2000, Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: Influence of margin status and systemic therapy on local recurrence, J Clin Oncol, 18, 1668, 10.1200/JCO.2000.18.8.1668 Jones, 2009, Impact of pathological characteristics on local relapse after breast-conserving therapy: A subgroup analysis of the EORTC boost versus no boost trial, J Clin Oncol, 27, 4939, 10.1200/JCO.2008.21.5764 Werkhoven, 2011, Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial, Radiother Oncol, 100, 101, 10.1016/j.radonc.2011.07.004 Gage, 1996, Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy, Cancer, 78, 1921, 10.1002/(SICI)1097-0142(19961101)78:9<1921::AID-CNCR12>3.0.CO;2-# Esteva, 2004, Prognostic molecular markers in early breast cancer, Breast Cancer Res, 6, 109, 10.1186/bcr777 Payne, 2008, Predictive markers in breast cancer—The present, Histopathology, 52, 82, 10.1111/j.1365-2559.2007.02897.x 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 Ahlin, 2007, Ki67 and cyclin A as prognostic factors in early breast cancer, Histopathology, 51, 491, 10.1111/j.1365-2559.2007.02798.x Colozza, 2005, Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now?, Ann Oncol, 16, 1723, 10.1093/annonc/mdi352 Jung, 2009, Ki-67 expression gives additional prognostic information on St. Gallen 2007 and adjuvant! Online risk categories in early breast cancer, Ann Surg Oncol, 16, 1112, 10.1245/s10434-009-0334-7 de Azambuja, 2007, Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients, Br J Cancer, 96, 1504, 10.1038/sj.bjc.6603756 Elkhuizen, 1999, Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: A case-control study of histological factors and alterations in oncogene expression, Int J Radiat Oncol Biol Phys, 45, 73, 10.1016/S0360-3016(99)00158-3 Sorlie, 2003, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A, 100, 8418, 10.1073/pnas.0932692100 Perou, 1999, Distinctive gene expression patterns in human mammary epithelial cells and breast cancers, Proc Natl Acad Sci U S A, 96, 9212, 10.1073/pnas.96.16.9212 Dawood, 2011, Defining breast cancer prognosis based on molecular phenotypes: Results from a large cohort study, Breast Cancer Res Treat, 126, 185, 10.1007/s10549-010-1113-7 Nguyen, 2008, Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy, J Clin Oncol, 26, 2373, 10.1200/JCO.2007.14.4287 Voduc, 2010, Breast cancer subtypes and the risk of local and regional relapse, J Clin Oncol, 28, 1684, 10.1200/JCO.2009.24.9284 Kiess, 2011, Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer, Cancer, 10.1002/cncr.26484 Chang, 2005, Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival, Proc Natl Acad Sci U S A, 102, 3738, 10.1073/pnas.0409462102 Chi, 2006, Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers, PLoS Med, 3, e47, 10.1371/journal.pmed.0030047 Nielsen, 2006, Loco-regional recurrence after mastectomy in high-risk breast cancer—Risk and prognosis, Radiother Oncol, 79, 147, 10.1016/j.radonc.2006.04.006 Jagsi, 2005, Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: Implications for postmastectomy radiation, Int J Radiat Oncol Biol Phys, 62, 1035, 10.1016/j.ijrobp.2004.12.014 de Bock, 2006, Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: Long-term results of European organisation for research and treatment of cancer studies, Eur J Cancer, 42, 351, 10.1016/j.ejca.2005.10.006 Fredholm, 2009, Breast cancer in young women: Poor survival despite intensive treatment, PLoS ONE, 4, e7695, 10.1371/journal.pone.0007695 Willner, 1997, Locoregional recurrence of breast cancer following mastectomy: Always a fatal event?, Int J Radiat Oncol Biol Phys, 37, 853, 10.1016/S0360-3016(96)00556-1 Taghian, 2006, J Clin Oncol, 24, 3927, 10.1200/JCO.2006.06.9054 de la Rochefordiere, 1993, Age as prognostic factor in premenopausal breast carcinoma, Lancet, 341, 1039, 10.1016/0140-6736(93)92407-K Kyndi, 2008, The Danish breast cancer cooperative group: Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer, J Clin Oncol, 26, 1419, 10.1200/JCO.2007.14.5565 Kunkler, 2008, Elucidating the role of chest wall irradiation in “intermediate-risk” breast cancer: The MRC/EORTC SUPREMO trial, Clin Oncol R (Coll Radiol), 20, 31, 10.1016/j.clon.2007.10.004 Cheng, 2006, Genomic prediction of locoregional recurrence after mastectomy in breast cancer, J Clin Oncol, 24, 4594, 10.1200/JCO.2005.02.5676 Voogd, 2001, Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: Pooled results of two large European randomized trials, J Clin Oncol, 19, 1688, 10.1200/JCO.2001.19.6.1688 Garcia-Etienne, 2009, Breast-conserving surgery in BRCA1/2 mutation carriers: Are we approaching an answer?, Ann Surg Oncol, 16, 3380, 10.1245/s10434-009-0638-7 Robson, 1999, Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations, J Natl Cancer Inst, 91, 2112, 10.1093/jnci/91.24.2112 Haffty, 2002, Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status, Lancet, 359, 1471, 10.1016/S0140-6736(02)08434-9 Pierce, 2006, Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer, J Clin Oncol, 24, 2437, 10.1200/JCO.2005.02.7888 Pierce, 2000, Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations, J Clin Oncol, 18, 3360, 10.1200/JCO.2000.18.19.3360 Shanley, 2006, Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom, Clin Cancer Res, 12, 7025, 10.1158/1078-0432.CCR-06-1244 Amundson, 2008, Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute anticancer drug screen, Cancer Res, 68, 415, 10.1158/0008-5472.CAN-07-2120 Torres-Roca, 2005, Prediction of radiation sensitivity using a gene expression classifier, Cancer Res, 65, 7169, 10.1158/0008-5472.CAN-05-0656 Rødningen, 2008, Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis, Radiother Oncol, 86, 314, 10.1016/j.radonc.2007.09.013 Russell, 1998, Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer, Int J Radiat Biol, 73, 661, 10.1080/095530098141915 Peacock, 2000, Cellular radiosensitivity and complication risk after curative radiotherapy, Radiother Oncol, 55, 173, 10.1016/S0167-8140(00)00173-0 Helland, 2006, Radiation-induced effects on gene expression: An in vivo study on breast cancer, Radiother Oncol, 80, 230, 10.1016/j.radonc.2006.07.007